The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression

The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: رویا دولت خواه

کلمات کلیدی: Keywords: Hazard function, Luminal, Tumour cells

نشریه: 42228 , 7 , 13 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله رویا دولت خواه
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات هماتولوژی و انکولوژی
کد مقاله 67922
عنوان فارسی مقاله The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression
عنوان لاتین مقاله The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression
ناشر 4
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

ABSTRACT Introduction: The role of Enhancer-of-zeste homologue 2 (EZH2) in breast cancer invasion and progression may be attributed to EZH2-mediated epigenetic repression of tumour cells. Aim: The study aimed to assess the prognostic value of different luminal subtypes of breast cancer in association with EZH2 protein expression. Materials and Methods: A cross-sectional analytical research study on breast cancer women was performed. The four major molecular subtypes of breast cancer were defned, as follows: luminal A, luminal B, HER2-type, and Triple-Negative/Basallike (TNBC). Log Rank (Mantel-Cox) test of equality of survival function was then performed to assess statistical signifcance between groups. The effects of variables on Overall Survival (OS) and Event Free Survival (EFS), was then assessed to give adjusted Hazard Ratios (HRs) with 95% Confdence intervals (CIs). Results: Samples were collected for women with breast cancers, with follow-up data collected over a 5-year period, with the age range of 34-75 years. TNBC subgroup was twice as likely to have high EZH2 expression compared with the luminal A subgroup (as the reference group) (OR=2.06; 95% CI=0.22 to19.09), and the luminal B subgroup had a 35% reduced likelihood (OR=0.66; 95% CI=0.26 to1.70). Cox’s Regression analysis showed that the hazard of mortality was about 3 times more in HER2 subtype breast cancers than in the luminal A subgroup (HR=3.16; 95% CI: 1.30-15.45, P<0.005), while the Log Rank (Mantel-Cox) test showed a statistically signifcant difference in OS by molecular subtype at all-time points (p≤0.05). Conclusion: The results provide some interesting insights, confrming the prognostic differences by molecular subtypes, in relation to EZH2 protein expression. However, there remains controversy about the prognostic value of different molecular subtypes.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
رویا دولت خواهچهارم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
JCDR2019.pdf1398/04/24675090دانلود